Trial results from DESTINY-Breast06 indicate the effectiveness of fam-trastuzumab deruxtecan-nxki in delaying disease progression for patients with hormone receptor (HR)–positive and HER2-low ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback